Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 89c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $254.04 +2.29%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.20, $0.89 better than the analyst estimate of $3.31. Revenue for the quarter came in at $838.1 million versus the consensus estimate of $832.52 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Prenetics Global (PRE) Tops Q2 EPS by 18c
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
